PB2701: SAFETY OF 30 MINUTES INFUSION OF RITUXIMAB BIOSIMILAR. A COHORT STUDY.

PB2701: SAFETY OF 30 MINUTES INFUSION OF RITUXIMAB BIOSIMILAR. A COHORT STUDY.

Bibliographic Details
Main Authors:	Laida Cuevas Palomares, Ernesto Pérez, Ariane Unamunzaga Cilaurren, Xabier Gutierrez Lopez De Ocariz, Buenaventura Buendia Ureña, Carmen Molinillo Fernández, Begoña Benito Ibarrondo, Ana Cordero Osua, Beatriz Benitez Delgado, Miguel Andrés Moralejo, Juan García Albás, Jose Guinea de Castro
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000977476.10247.9d

Similar Items

Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima)
by: Ernesto Pérez‐Persona, et al.
Published: (2023-11-01)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
by: Arnold G. Vulto
Published: (2019-12-01)

2.701 Introduction to Naval Architecture (13.400), Fall 2004
by: Herbein, David, et al.
Published: (2004)

Introduction of Biosimilar Rituximab: A Hospital Perspective
by: Simon Cheesman
Published: (2021-01-01)

Efficacy and safety of rituximab biosimilar in refractory lupus
by: Nantakarn Pongtarakulpanit, et al.
Published: (2020-12-01)

Safety of switching between rituximab biosimilars in onco-hematology
by: Silvana A. M. Urru, et al.
Published: (2021-03-01)

Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting
by: Ana Muntañola, et al.
Published: (2023-02-01)

Evidence of Co-learning through a Relational Pedagogy: Indigenizing the Curriculum through MIKM 2701
by: Emily Root, et al.
Published: (2019-05-01)

Joyos de Tholoza, "L’autrier el dous temps de pascor" (BdT 270.1)
by: Sabrina Galano
Published: (2016-06-01)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
by: Subramanian J, et al.
Published: (2017-04-01)

IMMUNOLOGICAL EFFECTS OF A RITUXIMAB BIOSIMILAR (ACELBIA, BIOCAD) IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. S. Avdeeva, et al.
Published: (2018-11-01)

Comparison of the efficacy and safety of the original rituximab and its biosimilar in routine clinical practice
by: D. A. Kusevich, et al.
Published: (2022-06-01)

Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives
by: Carla Rognoni, et al.
Published: (2018-06-01)

Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study
by: Roja Toosi, et al.
Published: (2021-01-01)

Intensive Safety Monitoring of Rituximab (Biosimilar Novex® and the Innovator) in Pediatric Patients With Complex Diseases
by: Natalia Riva, et al.
Published: (2022-01-01)

P1224: EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS
by: A. Haujir, et al.
Published: (2022-06-01)

PB2341: EARLY MORTALITY VARIABLES IN PATIENTS OLDER THAN 75 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA
by: Mónica Fernández Pérez, et al.
Published: (2023-08-01)

CURRENT APPROACH TO DEVELOPMENT OF BIOSIMILAR PRODUCTS CONTAINING MONOCLONAL ANTIBODIES AS AN ACTIVE SUBSTANCE – NON-CLINICAL AND CLINICAL STUDIES OF THE FIRST RUSSIAN RITUXIMAB BIOSIMILAR, ACELLBIA®
by: S. M. Alekseev, et al.
Published: (2015-04-01)

Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy
by: A. S. Avdeeva, et al.
Published: (2021-09-01)

The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, “BIOCAD”) in patients with rheumatoid arthritis
by: A S Avdeeva, et al.
Published: (2019-05-01)

Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice
by: D. A. Kusevich, et al.
Published: (2019-01-01)

Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study
by: Arthur Mageau, et al.
Published: (2023-12-01)

Efficacy and safety of biosimilar rituximab in the treatment of pemphigus vulgaris: a single center experience of 12 cases
by: Federico Bardazzi, et al.
Published: (2022-01-01)

Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets
by: R. O. Dreval
Published: (2018-06-01)

Relationship between laboratory biomarkers and ultrasonographic signs of inflammation in patients with rheumatoid arthritis treated with a rituximab biosimilar
by: A. S. Avdeeva, et al.
Published: (2022-06-01)

RITUXIMAB BIOSIMILAR RTXM83 POST-MARKETING SURVEILLANCE IN BRAZIL: EVALUATION OF THE ADVERSE EVENTS SPONTANEOUSLY REPORTED TO PHARMACOVIGILANCE
by: AM Silva, et al.
Published: (2021-10-01)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
by: Yuankai Shi, et al.
Published: (2020-04-01)

Efficacy and safety of biosimilar rituximab (ZytuxTM) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia
by: Alaa Fadhil Alwan, et al.
Published: (2020-12-01)

The beginning of the new era of monoclonal antibodies biosimilars use in oncology:current international guidelines and the results of clinical trial of the first Russian rituximab biosimilar in patients with B-cell non-Hodgkin’s lymphoma
by: K D Kaplanov, et al.
Published: (2014-06-01)

Biosimilars
by: Emel Bülbül Başkan
Published: (2022-04-01)

THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL
by: E. L. Nasonov, et al.
Published: (2017-09-01)

Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa
by: Almaaytah A
Published: (2020-09-01)

Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar
by: Farzad Fatehi, et al.
Published: (2021-08-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2020-12-01)

The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study)
by: M. A. Korolev, et al.
Published: (2021-01-01)

Estudos de medicamentos biosimilares Studies on biosimilar medications
by: Winston Bonetti Yoshida
Published: (2010-09-01)

Prescribing biosimilars
by: Aronson, J, et al.
Published: (2018)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
by: Alina Uifălean, et al.
Published: (2018-09-01)

Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting
by: Viktoriya Pavlych, et al.
Published: (2020-09-01)